Spero Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $2.0M | $335.0K |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $32.9M | $26.3M |
| SG&A Expense | $10.8M | $7.2M |
| Operating Income | $-41.7M | $-33.2M |
| Operating Margin | -2,108.6% | -9,916.7% |
| Interest Expense | — | — |
| Pretax Income | $-39.9M | $-32.6M |
| Income Tax Expense | $0 | $0 |
| Net Income | $-38.7M | $-25.5M |
| Net Margin | -1,957.7% | -7,609.3% |
| EPS (Basic) | $-17.82 | $-95.87 |
| EPS (Diluted) | $-17.82 | $-95.87 |
| Shares Outstanding (Basic) | 14.4M | 0 |
| Shares Outstanding (Diluted) | 14.4M | 0 |
| Dividends Per Share | — | — |